Long-term use of burosumab for the treatment of tumor-induced osteomalacia

被引：0
作者：
C. Crotti
F. Zucchi
C. Alfieri
R. Caporali
M. Varenna
机构：
[1] ASST-Pini-CTO,Department of Rheumatology
[2] University of Milan,Department of Clinical Sciences and Community Health
[3] Foundation Ca’ Granda IRCCS Ospedale Maggiore Policlinico,Department of Nephrology, Dialysis and Renal Transplant
来源：
Osteoporosis International | 2023年 / 34卷
关键词：
Burosumab; FGF23; Osteomalacia; Tumor-induced bone disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：201 / 206
页数：5
相关论文
共 215 条
[1]  
Minisola S(2017)Tumour-induced osteomalacia Nat Rev Dis Primers 3 17044-142
[2]  
Peacock M(2021)Tumor-induced osteomalacia Calcif Tissue Int 108 128-127
[3]  
Fukumoto S(2018)Tumor-induced osteomalacia Osteoporos Sarcopenia 4 119-1267
[4]  
Cipriani C(2005)Tumor-induced osteomalacia JAMA 294 1260-2193
[5]  
Pepe J(2021)Tumor induced osteomalacia: a single center experience on 17 patients Bone 152 2187-30
[6]  
Tella SH(2017)Tumor-induced osteomalacia: experience from a South American academic center Osteoporos Int 28 1-1354
[7]  
Collins MT(2004)Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature Am J Surg Pathol 28 1348-227
[8]  
Florenzano P(2009)RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia Am J Surg Pathol 33 222-3581
[9]  
Hartley IR(2014)68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT Bone 64 3575-1398
[10]  
Jimenez M(2016)(68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia J Clin Endocrinol Metab 101 1386-721
12345678910